Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study.

Oscar Fernández,Guillermo Izquierdo,Eduardo Aguera,Cristina Ramo,Miguel Hernandez,Diego Silva,Rob Walker,Helmut Butzkueven,Chenyu Wang,Michael Barnett

Multiple sclerosis journal - experimental, translational and clinical（2020）

引用 7|浏览6

暂无评分

摘要

Fingolimod appeared equally effective as first- or second-line therapy in relapsing MS. There was a trend for better outcomes with fingolimod in treatment-naïve patients than in those previously treated with >1 iDMT.

查看译文

关键词

Beta-interferon,clinical trial,disease-modifying therapies,glatiramer acetate,outcome measurement,relapsing/remitting

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要